MedTrace Logo

Renal Pelvic Denervation Pilot Trial

NCT07005050 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-08

No results posted yet for this study

Summary

The RPD Pilot trial will evaluate the safety and effectiveness of Verve Medical's RPDTM renal denervation system for hypertensive patients with uncontrolled blood pressure despite use of two medications at a therapeutic dose.

The novelty of the RPDTM system relates to its placement via natural orifice into the renal pelvis (bilaterally) for delivery of radiofrequency energy to ablate the nerves that pass through the outer wall of the renal pelvis, a technique referred to as renal pelvic denervation (RPD).

Conditions

Interventions

DEVICE

RPD

Renal Pelvic Denervation

DRUG

Active hypertension medical therapy

Prespecified two medication regimen for control of hypertension

Sponsors & Collaborators

  • RQM+

    collaborator INDUSTRY

  • Dabl Ltd

    collaborator UNKNOWN

  • Medical Labs Memphis - MLM

    collaborator UNKNOWN

  • Verve Medical, Inc

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-30
Primary Completion
2026-10-30
Completion
2029-03-02
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07005050 on ClinicalTrials.gov